A comparison of the effect of growth factors on intestinal function and structure in short bowel syndrome

Short-Bowel Syndrome in Children — An Update in Management Strategies

“…EGF was given orally with foods in a daily dose of 100 µg/kg for six weeks The results showed improvement in nutrient absorption, increased tolerance with enteral feeding and possible improvement of infection rate. In contrast, Lukish et al failed to observe any changes in the small bowel epithelium after an experimental massive intestinal resection and utilization of EGF [80].…”

Effects of Insulin-Like Growth Factor-1 on Short Bowel Syndrome without Ileocecal Valve in Rats

“…Since it is well recognized that liver-derived IGF-1 contributes to a large part of circulating IGF-1 [16], it is suggested that plasma IGF-1 might be lower in SBR including ICV than in ICV preservation. Supplemented therapies for short bowel syndrome have been studied using growth hormone, IGF-1, epidermal growth factor, glutamine and glucagon-like peptide to facilitate intestinal adaptation and improve nutritional status [15,[17][18][19]. Administration of IGF-1 after 60% small bowel and cecal resection has been shown to play an important role in colonic adaptation which is indicated by significantly enhanced colonic mucosal growth and water absorption [15].…”

“…Administration of IGF-1 after 60% small bowel and cecal resection has been shown to play an important role in colonic adaptation which is indicated by significantly enhanced colonic mucosal growth and water absorption [15]. Epidermal growth factor and IGF-1 enhance nutrient absorption after SBR by improving enterocyte cellular function [18]. Hormonal therapy with growth hormone, IGF-1 and glucagon-like peptide-2 can improve short-term weight gain after SBR [19].…”

New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome

“…74 Epidermal growth factor stimulates messenger RNA, DNA, and protein synthesis in many cell types, 75 and has been shown to increase villus height, protein content, and the uptake of glucose and electrolytes in the intestine. 44,[76][77][78] Lessons from animal models Administration of EGF has been shown to enhance intestinal adaptation and preserve bowel morphology and function following massive small bowel resection by stimulating the proliferation of both enterocytes and myocytes (Table 3. 77,79 In mice devoid of EGF or exhibiting a disrupted EGF receptor (EGFR), intestinal adaptation is markedly inhibited, and the characteristic adaptationinduced increase in villus height, crypt depth, ileal DNA and protein content is attenuated in these mice following 50% small bowel resection. 81,82 Following systemic and oral administration of recombinant EGF (rEGF) to EGF-deficient mice, structural adaptation was comparable to wild-type mice.…”

“…44 Similarly, rEGF administration in a rat model of SBS failed to enhance mucosal thickness, villus height, crypt depth, muscularis propria height, and microvillus height above that seen in the wild-type resected rats. 76,80 Hence, the ability of rEGF to enhance intestinal adaptation following resection remains contentious. Differences in the administration route, EGF dose, and resection model utilized by each study may be responsible for the lack of agreeability amongst studies (Table 3).…”